A new class action lawsuit has been filed against healthcare companies Lipo-Flavonoid LLC and Bridges Consumer Healthcare, LLC, alleging deceptive marketing practices related to a dietary supplement.
According to the lawsuit filed by plaintiff Kirk Cahill, the case centers on the marketing of Lipo-Flavonoid, a dietary supplement advertised as an effective treatment for tinnitus, commonly known as "ringing in the ears." According to the plaintiff, the product’s claims are misleading and lack scientific support. Despite assertions that the product is "#1 ENT Doctor Recommended" and "Clinically Shown to Help Manage Ear Ringing," studies have shown that Lipo-Flavonoid is no more effective than a placebo. Plaintiff Kirk Cahill claims he purchased the product based on these statements but found them to be false. He alleges violations of New York General Business Law sections 349 and 350 and breach of express warranty.
The lawsuit references prior investigations into similar advertising claims made by Clarion Brands, which previously marketed Lipo-Flavonoid before being acquired by Bridges Consumer Healthcare in 2021. Investigations by the National Advertising Division (NAD) and National Advertising Review Board (NARB) determined that earlier advertising lacked adequate scientific support. According to the plaintiff, Bridges Consumer Healthcare continued similar marketing practices under revised branding without altering the product’s formulation or addressing the prior findings.
The plaintiff seeks monetary damages, restitution, statutory damages under New York law, punitive damages, and reimbursement of legal costs. The proposed class includes a nationwide group and a subclass of New York purchasers who bought Lipo-Flavonoid based on the disputed advertising.
The plaintiff is represented by attorney Philip J. Furia of Furia Law LLC. The case was filed in the United States District Court for the Eastern District of New York.